Sequana Medical NV

Sequana Medical NV is a Belgian company founded in 2006 that develops innovative treatments for fluid overload using its proprietary alfa pump® and DSR® (Direct Sodium Removal) technologies. Sequana Medical NV has its headquarters in Ghent, Belgium, and has offices in Zurich, Switzerland, and Düsseldorf, Germany. As of May 9, 2023, Sequana Medical NV has a market capitalization of EUR 101.4 million based on a share price of EUR 3.36.

Sequana Medical NV has developed two innovative technologies: the alfa pump® system and the DSR® (Direct Sodium Removal) therapy. The alfa pump® system is a fully implantable device that automatically pumps excess fluid from the abdomen into the bladder, where it is naturally eliminated through urination. The alfa pump® system has been approved in Europe since 2011 and has been used by more than 900 patients. The alfa pump® system is currently under clinical investigation in the US and Canada (POSEIDON Study) for patients with refractory or recurrent ascites due to cirrhosis.

Sequana Medical NV has the vision to become a leader in innovative treatment solutions for fluid overload. The company is currently conducting clinical trials for its alfa pump® system in the US and Canada for patients with refractory or recurrent ascites due to cirrhosis. The company is also developing its DSR® therapy for patients with heart failure and diuretic-resistant fluid overload.

Foundation: 2006

Headquarters: Ghent, Belgium

Website: https://www.sequanamedical.com/